Lachlan Brown
Stock Analyst at William Blair
(1.87)
# 3,242
Out of 4,988 analysts
10
Total ratings
37.5%
Success rate
6.96%
Average return
Main Sectors:
Stocks Rated by Lachlan Brown
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MANH Manhattan Associates | Downgrades: Neutral | $270 → $200 | $217.71 | -8.13% | 2 | Jun 10, 2025 | |
| HROW Harrow | Initiates: Outperform | n/a | $44.34 | - | 1 | Jun 10, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Outperform | n/a | $4.54 | - | 1 | Apr 8, 2025 | |
| OCUL Ocular Therapeutix | Initiates: Outperform | n/a | $12.10 | - | 1 | Apr 8, 2025 | |
| SNPS Synopsys | Initiates: Buy | $600 | $495.50 | +21.09% | 1 | Jan 13, 2025 | |
| CDNS Cadence Design Systems | Initiates: Buy | $350 | $373.35 | -6.25% | 1 | Jan 13, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Outperform | n/a | $23.01 | - | 1 | Oct 16, 2024 | |
| DSGX The Descartes Systems Group | Initiates: Neutral | $90 | $101.85 | -11.63% | 1 | May 14, 2024 | |
| SPSC SPS Commerce | Initiates: Buy | $220 | $107.19 | +105.24% | 1 | May 14, 2024 |
Manhattan Associates
Jun 10, 2025
Downgrades: Neutral
Price Target: $270 → $200
Current: $217.71
Upside: -8.13%
Harrow
Jun 10, 2025
Initiates: Outperform
Price Target: n/a
Current: $44.34
Upside: -
Kalaris Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $4.54
Upside: -
Ocular Therapeutix
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $12.10
Upside: -
Synopsys
Jan 13, 2025
Initiates: Buy
Price Target: $600
Current: $495.50
Upside: +21.09%
Cadence Design Systems
Jan 13, 2025
Initiates: Buy
Price Target: $350
Current: $373.35
Upside: -6.25%
Apellis Pharmaceuticals
Oct 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $23.01
Upside: -
The Descartes Systems Group
May 14, 2024
Initiates: Neutral
Price Target: $90
Current: $101.85
Upside: -11.63%
SPS Commerce
May 14, 2024
Initiates: Buy
Price Target: $220
Current: $107.19
Upside: +105.24%